The estimated Net Worth of Wei Wu He is at least $14.1 Milión dollars as of 13 June 2022. Wei He owns over 88,154 units of CASI Pharmaceuticals Inc stock worth over $4,866,375 and over the last 10 years he sold CASI stock worth over $0. In addition, he makes $9,269,690 as Executive Chairman of the Board a Chief Executive Officer at CASI Pharmaceuticals Inc.
Wei has made over 19 trades of the CASI Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 88,154 units of CASI stock worth $272,396 on 13 June 2022.
The largest trade he's ever made was buying 4,152,426 units of CASI Pharmaceuticals Inc stock on 22 July 2020 worth over $7,889,609. On average, Wei trades about 481,338 units every 61 days since 2014. As of 13 June 2022 he still owns at least 644,553 units of CASI Pharmaceuticals Inc stock.
You can see the complete history of Wei He stock trades at the bottom of the page.
Dr. Wei-Wu He Ph.D. serves as Executive Chairman of the Board, Chief Executive Officer of the Company. Dr. He has served as CEO and Chairman since April 2, 2019. Dr. He served as Executive Chairman of the Company from February 23, 2018 to April 2, 2019, as Chairman of the Company from May 2013 to February 23, 2018, and as Executive Chairman from February 2012 to May 2013. Dr. He has served as Chairman of OriGene Technologies, Inc. since 1995 and served as its Chief Executive Officer from 1995 through April 2, 2019. He also is the founder and General Partner of Emerging Technology Partners, LLC, a life sciences focused venture fund established in 2000. Dr. He has been involved in founding or funding over 20 biotech companies throughout his career, some of which went on to be acquired by significantly larger firms. In the earlier part of his career, Dr. He was one of the first few scientists at Human Genome Sciences, and prior to that, was a research fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He is an author to more than 25 research publications and inventor of over 30 issued patents. Dr. He received his Ph.D. from Baylor College of Medicine and MBA from The Wharton School of University of Pennsylvania.
As the Executive Chairman of the Board a Chief Executive Officer of CASI Pharmaceuticals Inc, the total compensation of Wei He at CASI Pharmaceuticals Inc is $9,269,690. There are no executives at CASI Pharmaceuticals Inc getting paid more.
Wei He is 54, he's been the Executive Chairman of the Board a Chief Executive Officer of CASI Pharmaceuticals Inc since 2019. There are 11 older and no younger executives at CASI Pharmaceuticals Inc. The oldest executive at CASI Pharmaceuticals Inc is Rajesh Shrotriya, 76, who is the Independent Director.
Wei's mailing address filed with the SEC is CASI PHARMACEUTICALS, INC., 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE, MD, 20850.
Over the last 12 years, insiders at CASI Pharmaceuticals Inc have traded over $0 worth of CASI Pharmaceuticals Inc stock and bought 30,834,178 units worth $51,898,666 . The most active insiders traders include Wei Wu He, Rajesh C Md Shrotriya a Pharmaceuticals Inc Spectru.... On average, CASI Pharmaceuticals Inc executives and independent directors trade stock every 91 days with the average trade being worth of $6,141,555. The most recent stock trade was executed by James Huang on 6 September 2022, trading 55,573 units of CASI stock currently worth $229,516.
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is located in Beijing, China. The Company has built a commercial team of over 70 hematology and oncology sales and marketing specialists based in China.
CASI Pharmaceuticals Inc executives and other stock owners filed with the SEC include: